Nivestym is not the first biosimilar of Neupogen, which helps chemotherapy patients recover, but it reflects the Food and Drug Administration's emphasis on bringing more biosimilars to market.
Hospitals have adopted a take-no-prisoners approach in the fight with Big Pharma over the 340B drug discount program. Can this strategy hold as Congress, oversight agencies, the courts and the Trump administration ratchet up scrutiny of the program?
The maker of a permanent contraceptive implant subject to thousands of injury reports from women and repeated safety restrictions by regulators said Friday that it will stop selling the device in the U.S.
While some proton therapy centers across the country have reportedly struggled to stay profitable, officials at University Hospitals in Cleveland say they've found the "sweet spot" two years after the health system opened its own $30 million center.
Long before Amazon announced its joint healthcare venture and PillPack acquisition, the e-commerce giant has been slowly growing its portfolio of medical supplies offered through its Amazon Business platform.